Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

Table 3 Therapeutic efficacy in patients with stage A or B and stage C, n (%)

	BCLC A or B			BCLC C
	Lenvatinib + TACE + PD-1 (n = 11)	Lenvatinib + TACE (n = 5)	P value	Lenvatinib + TACE + PD-1 (n = 34)	Lenvatinib + TACE (n = 15)	P value
CR	0 (0)	0 (0)		0 (0)	0 (0)
PR	8 (72.7)	1 (20)		12 (35.3)	3 (20.0)
SD	3 (27.3)	2 (40)		19 (55.9)	7 (46.7)
PD	0 (0)	2 (40)		3 (8.8)	5 (33.3)
ORR	8 (72.7)	1 (20)	0.0772	12 (35.3)	3 (20)	0.2352
DCR	11(100)	3 (60)	0.0832	31 (91.2)	10 (66.7)	0.0472

¹χ² test.

²Fisher’s exact test.

BCLC: Barcelona Clinic Liver Cancer; DCR: Disease control rate; ORR: Objective response rate; PD: Progressive disease; PR: Partial response; SD: Stable disease; PD-1: Programmed death receptor-1; TACE: Transarterial chemoembolization.